The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users

Esmethadone (REL-1017) is the opioid-inactive dextro-isomer of methadone and a low-affinity, low-potency uncompetitive NMDA receptor antagonist. In a Phase 2, randomized, double-blind, placebo-controlled trial, esmethadone showed rapid, robust, and sustained antidepressant effects. Two studies were...

Descripción completa

Detalles Bibliográficos
Autores principales: Shram, Megan J., Henningfield, Jack E., Apseloff, Glen, Gorodetzky, Charles W., De Martin, Sara, Vocci, Frank L., Sapienza, Frank L., Kosten, Thomas R., Huston, Jeff, Buchhalter, August, Ashworth, Judy, Lanier, Ryan, Folli, Franco, Mattarei, Andrea, Guidetti, Clotilde, Comai, Stefano, O’Gorman, Cedric, Traversa, Sergio, Inturrisi, Charles E., Manfredi, Paolo L., Pappagallo, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247777/
https://www.ncbi.nlm.nih.gov/pubmed/37286536
http://dx.doi.org/10.1038/s41398-023-02473-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247777/
https://www.ncbi.nlm.nih.gov/pubmed/37286536
http://dx.doi.org/10.1038/s41398-023-02473-8

Ejemplares similares